Tuberculosis (TB)

The use of delamanid in the treatment of multidrug-resistant tuberculosis

Interim policy guidance

Authors:
World Health Organization

Publication details

Number of pages: 80
Publication date: 2014
Languages: English
WHO reference number: WHO/HTM/TB/2014.23

Downloads

Overview

The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient’s eligibility criteria and safety conditions, and presents the necessary caveats relevant to the use of this new drug for which Phase III clinical trial data are not yet available.